PA
CGEM icon

Parallel Advisors’s Cullinan Oncology CGEM Stock Holding History

Parallel Advisors’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.1K Sell
1,873
-22
-1% -$327 ﹤0.01% 2376
2026
Q1 		$26.9K Hold
1,895
– – ﹤0.01% 2336
2025
Q4 		$19.6K Buy
1,895
+22
+1% +$198 ﹤0.01% 2304
2025
Q3 		$11.1K Buy
1,873
+1,809
+2,827% +$13.2K ﹤0.01% 2499
2025
Q2 		$482 Buy
+64
New +$514 ﹤0.01% 3312
2025
Q1 		– Sell
-1,317
Closed -$16K – 3533
2024
Q4 		$16K Hold
1,317
– – ﹤0.01% 2240
2024
Q3 		$22K Hold
1,317
– – ﹤0.01% 2047
2024
Q2 		$23K Hold
1,317
– – ﹤0.01% 1907
2024
Q1 		$22.4K Hold
1,317
– – ﹤0.01% 1916
2023
Q4 		$13.4K Buy
+1,317
New +$11.7K ﹤0.01% 2157
2023
Q2 		– Sell
-36
Closed -$368 – 3389
2023
Q1 		$368 Buy
+36
New +$397 ﹤0.01% 3196
2022
Q4 		– Sell
-10
Closed – – 3374
2022
Q3 		$0 Sell
10
-18
-64% -$243 ﹤0.01% 3177
2022
Q2 		$0 Buy
28
+22
+367% +$249 ﹤0.01% 3032
2022
Q1 		$0 Buy
+6
New +$81 ﹤0.01% 3001

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Parallel Advisors's CGEM Position: Q2 2026 in Review

Parallel Advisors reduced its Cullinan Oncology (CGEM) stake by 1.2% in Q2 2026, selling an estimated $327 and leaving 1,873 shares worth $34.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2376.

Parallel Advisors first reported a position in CGEM in Q1 2022 and has held it in 14 quarters since. 121 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Parallel Advisors held 1,873 shares of Cullinan Oncology worth $34.1K as of Q2 2026.
  • Parallel Advisors sold 22 Cullinan Oncology shares in Q2 2026, an estimated $327.
  • Cullinan Oncology made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2376 holding.
  • Parallel Advisors first reported a position in Cullinan Oncology in Q1 2022 and has held it in 14 quarters since.
  • 121 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.